anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Chlorpromazine should generally not be used in pediatric patients under 6 months of age except where potentially lifesaving. It should not be used in conditions for which specific pediatric dosages have not been established.

Severe Behavioral Problems   


Outpatients – Select route of administration according to severity of patient's condition and increase dosage gradually as required. Oral: ¼ mg/pound body weight every four to six hours, as needed (e.g., for 40-pound child – 10 mg every four to six hours).  


Hospitalized Patients – As with outpatients, start with low doses and increase dosage gradually. In severe behavior disorders higher dosages (50 to 100 mg daily and in older children, 200 mg daily or more) may be necessary. There is little evidence that behavior improvement in severely disturbed mentally retarded patients is further enhanced by doses beyond 500 mg per day.  


Nausea and Vomiting– Dosage and frequency of administration should be adjusted according to the severity of the symptoms and response of the patient. The duration of activity following intramuscular administration may last up to 12 hours. Subsequent doses may be given by the same route if necessary. Oral: ¼ mg/pound body weight (e.g., 40-pound child – 10 mg every 4 to six hours).  


Presurgical Apprehension–¼ mg/pound body weight orally 2 to 3 hours before operation.
The invention relates to a novel technology which utilizes spin echo acquisition to process MR measurement for an ultrashort T2<*> relaxation. The ultrashort T2<*> relaxation can be used for definiting quantity for high-concentration ferrum labeling cells high concentration during cellular transport and treatment. In an embodiment as an example, a signal is induced by a low-oblique chamfer angle radio-frequency pulse. When the pulse is activated, a gradient is read and is used for forming echo. The time between the radio-frequency pulse and the gradient reading center is defined as TE. In the tissue with high-concentration ferrum labeling cells, T2<*> may be less than 1 millisecond. Thereby, the signal can be decayed into a noise level via the echo time of a plurality of milliseconds. More T2<*> are in the SPIO labeling cells, thereby the signal obtained via the spin echo is bigger than the signal formed from the gradient echo so as to avoid related negative effects that numerous signals during imaging are lost. Then, an ultrashort T2<*> relaxation picture can be stacked on the common ultrashort T2<*> relaxation picture to generate a final T2<*> picture of a view field.
Treatment will be compromised of 8 weeks of standard care plus OMT. Each physician will maintain the same patient at recurring sessions. Osteopathic treatment is performed for 30 minutes and the techniques applied are highly individualized to the patient needs (i.e., techniques are selected based on structure/function, and techniques change over time based on treatment response). In an effort to standardize treatment, we will limit the study protocol to the following designated techniques: facilitated positional release treatment, high velocity low amplitude treatment, articulatory treatment, strain-counterstrain, muscle energy treatment, myofascial release treatment, soft tissue treatment.
Gynecological emergencies can often present with a myriad of non-specific signs and symptoms, posing a diagnostic challenge to the clinician. They can be grossly divided into uterine or adnexal pathologies. Uterine pathologies can be secondary to intracavitary accumulation of blood [like in patients with transverse vaginal septum, Robert's uterus, accessory and cavitated uterine mass, unicornuate uterus with contralateral non-communicating functional horn], bleeding per vaginum [like in patients with retained products of conception, enhanced myometrial vascularity], pyometra [secondary to pelvic inflammatory disease, cervical obstruction secondary to benign and malignant causes] or complications of fibroids [like red degeneration, torsion of subserosal fibroid]. The adnexal pathologies can range from ectopic pregnancy in a urine pregnancy test (UPT) positive patient to haemorrhagic ovarian cyst, ovarian torsion, ruptured dermoid cyst and tubo-ovarian abscess in a UPT negative patient. Multimodality imaging including ultrasound (USG), computed tomography (CT) scan and magnetic resonance imaging (MRI) can narrow down the differentials and help in formulating an accurate diagnosis. The objective of this article is to familiarize the readers with multimodality imaging findings in common as well as uncommon acute gynecological emergencies and provide an algorithmic imaging approach for acute gynecological emergencies. USG is typically used as the first line diagnostic modality in diagnosis of acute gynecological emergencies. CT scan & MRI are helpful as a problem-solving tool in acute gynecological emergencies when USG findings are indeterminate.
Connexin43 (Cx43) is the most abundant gap junction protein present in the mesenchymal lineage. In mature adipocytes, Cx43 mediates white adipose tissue (WAT) beiging in response to cold exposure and maintains the mitochondrial integrity of brown adipose tissue (BAT). We found that genetic deletion of Gja1 (Cx43 gene) in cells that give rise to chondro-osteogenic and adipogenic precursors driven by the Dermo1/Twist2 promoter led to lower body adiposity and partial protection against the weight gain and metabolic syndrome induced by a high-fat diet (HFD) in both sexes. These protective effects were related to increased locomotion, fuel utilization, energy expenditure, nonshivering thermogenesis, and better glucose tolerance in conditionally Gja1-ablated mice. Accordingly, Gja1-mutant mice exhibited reduced adipocyte hypertrophy, partially preserved insulin sensitivity, increased BAT lipolysis, and decreased whitening under HFD. This metabolic phenotype was not reproduced with more restricted Gja1 ablation in differentiated adipocytes, suggesting that Cx43 in adipocyte progenitors or other targeted cells restrains energy expenditures and promotes fat accumulation. These results reveal what we believe is a hitherto unknown action of Cx43 in adiposity, and offer a promising new pharmacologic target for improving metabolic balance in diabetes and obesity.
In studying patients in whom cardiac disease is known or suspected, care should be taken to assure continuous monitoring and treatment in accordance with safe, accepted clinical procedure. Infrequently, death has occurred 4 to 24 hours after Tc 99m Sestamibi use and is usually associated with exercise stress testing [see Warnings and Precautions (5.2)].

Pharmacologic induction of cardiovascular stress may be associated with serious adverse events such as myocardial infarction, arrhythmia, hypotension, bronchoconstriction and cerebrovascular events. Caution should be used when pharmacologic stress is selected as an alternative to exercise; it should be used when indicated and in accordance with the pharmacologic stress agent’s labeling.

Technetium Tc 99m Sestamibi has been rarely associated with acute severe allergic and anaphylactic events of angioedema and generalized urticaria. In some patients the allergic symptoms developed on the second injection during Tc 99m Sestamibi imaging. Patients who receive Technetium Tc 99m Sestamibi for either myocardial or breast imaging are receiving the same drug. Caution should be exercised and emergency equipment should be available when administering Technetium Tc 99m Sestamibi. Also, before administering Technetium Tc 99m Sestamibi Injection, patients should be asked about the possibility of allergic reactions to the drug.
The research design is a 2x2 factorial open-label cluster randomised controlled trial. The cluster (unit of randomization) is at the level of each local community senior's group, from whence participants will be recruited. Incontinent community-dwelling older women aged 60 years and older who have not sought care for their urinary symptoms in the last two years, but who experience incontinence at least twice weekly will be recruited through local community organizations. Eligible participants from each local community centre will be randomly assigned as a group to one of four interventions. The first intervention is participation in an interactive constructivist continence workshop. The second intervention involves receipt of an evidence-based self-management tool for incontinence. The third group will receive both interventions. The fourth group will act as the control group: they will simply be asked about their urinary symptoms and given a general talk on women's health. At the end of the study, the control group will be offered the self-management tool.
PURPOSE: A vegetable estrogen composition for preventing or relieving symptom of menopause or climacterium containing plant extract is provided to ensure vegetable estrogen activity and to relieve various symptoms due to estrogen deficiency. CONSTITUTION: A vegetable estrogen composition for preventing or relieving symptom of menopause or climactrium contains Cnidium monieri (L). Cuss extract as an active ingredient. The symptom includes blushing, diaphoresis, skin dryness, colpoxerosis, vaginal atrophy, and vaginosis. A vegetable estrogen composition for preventing or relieving estrogen-dependent diseases contains Cnidium monieri (L). Cuss extract as an active ingredient.
PURPOSE: To provide a method to effectively trap biological active substances in a sterol vesicle which is suitable for the dose in a living body so as to dose a larger amt. of water-soluble active substances and so as to make the dose of the water insoluble active substances easy. CONSTITUTION: This trapping method of water-insoluble compds. in a sterol vesicle consists of steps of dissolving water-insoluble compds. in an org. solvent, removing the org. solvent to leave a film consisting of the water-insoluble compds., and adding a sterol vesicle suspension comprising a salt of a sterol org. deriv. to the film. Or, the trapping method of water-insoluble compds. in a sterol vesicle consists of steps of dissolving both of water-insoluble compds. and a salt form of an org. acid deriv. of sterol which can form a double layer in an aq. phase in an org. solvent, vaporizing the org. solvent to leave a film containing the compds. and the salt of the org. acid deriv. of sterol, adding an aq. phase to the film, and shaking so as to form an opaque suspension liquid of a multilamellar vesicle which is completely closed.
This is a single-blind randomized controlled trial. Data were collected from 80 women who gave birth in the obstetrics clinic of a state hospital in the south of Turkey between December 2020 and June 2021. Participants who met the inclusion criteria were informed about the purpose of the study and the procedures to be performed, informed consent was obtained from those who agreed to participate, and women were assigned to the groups in line with a computer-based randomization program with an allocation ratio of 1:1. Block randomization could not be performed because of the different and long delivery processes. Data were collected in both groups at birth (latent phase, active phase, and transitional phase), within 24 hours of birth, and 6th-8th postpartum days after hospital admission and at least one hour of care. collected by the first author. The CONSORT directive was followed in the planning, implementation and writing of the research.
Background The advantages of single injection (SISB) and continuous interscalene brachial plexus block (CISB) over general anesthesia (GA) only have been previously reported. However, few studies extended their observations beyond 48 postoperative hours, and no study has compared the effects of SISB and CISB as sole anesthesia modalities with GA only. We undertook this randomized trial to compare the recovery profile of patients receiving SISB, CISB or GA for arthroscopic rotator cuff repair surgery through the first postoperative week. Our primary hypothesis was that highest NRS pain rating (worst pain score) at the end of the study week is lower for patients in the CISB group than for patients in the SISB or GA groups.

Methods After Institutional Review Board approval and informed consents were obtained, 71 patients of American Society of Anesthesiologists (ASA) physical status I-III, ≥18 years of age, and BMI≤35 kg/m2, scheduled for elective outpatient arthroscopic rotator cuff repair, were enrolled. CISB patients received 20 mL of 0.5% ropivacaine as bolus through the catheter whereas SISB patients received the same volume of injection through a needle. CISB patients received an infusion of 0.2% ropivacaine at 5mL/h with a patient controlled bolus of 5 mL hourly. GA only patients received a standardized general anesthetic. All patients were prescribed acetaminophen (500mg) with hydrocodone (7.5mg) every 4h as needed. CISB was discontinued 48 h after surgery. Postoperative highest pain scores (NRS) through the first postoperative week, time-to-first pain, analgesic consumption, fast-tracked postoperative care unit (PACU) bypass rate, length of PACU stay, time-to-discharge home, sleep duration, and related adverse effects were recorded in the PACU and at home on postoperative days 1, 2, 3, and 7.
The invention discloses an externally used medicine for curing acne containing honey and royal jelly, comprising tinidazole, miconazole, green ointment, honey, royal jelly and sterile water. The preparation method comprises the following operational steps: grinding metronidazole into powder, sieving; embedding metronidazole powder by miconazole and green ointment, stirring evenly; adding sterile water and stirring evenly; adding honey and royal jelly and stirring evenly. The formulation of the invention is reasonable, has effective effect on curing acne and realizes the aim of resolving the current problems and eliminating the root causes. The added two natural substances honey and royal jelly have the functions of antibiosis and anti inflammatory and can prevent cross infection and adverse effect of the medicine, prevent effectively melanin from precipitating, restore skin resiliency, and adjust skin pH value and oil water balance so that the skin can be white, soft and glossy. The combination of traditional Chinese medicine and western medicine can coordinate with each other and is difficult to generate drug resistance. The medicine is simple in processing and convenient in use, and provides an ideal medicine for cooperating with acne and operation treatment.
Four different doses were set, and three subjects in each dose plan received human umbilical cord mesenchymal stem cell injection successively. Each subject received a single dose of 6.0\*10\^6, 3.0\*10\^7, 6.0\*10\^7, and 9.0\*10\^7 cells / person.
Patients follow a standard of care treatment plan at the discretion of the primary oncologist. Beginning 6 months from the start of chemotherapy, patients undergo the geriatric assessment as in Arm I. Some patients complete the standard of care treatment plan via Telehealth.
PCT No. PCT/US94/06890 Sec. 371 Date Apr. 29, 1996 Sec. 102(e) Date Apr. 29, 1996 PCT Filed Jun. 17, 1994 PCT Pub. No. WO95/00849 PCT Pub. Date Jan. 5, 1995The adhesin 170 kDa subunit of Hm-1:IMSS strain of Entamoeba histolytica is encoded by a gene family that includes hgl1, hgl2 and a previously undescribed third gene, hgl3, for which the DNA and protein sequences are disclosed. All three of these heavy subunit genes were expressed in the amebae. Methods and reagents (both nucleic acid and immunological) which are specific for each of the genes, as well as reagents which detect common regions of all three hgl genes or their nucleic acid or protein products, are disclosed. Recombinantly produced heavy chain subunit of E. Histolytica Gal/GalNAc adherence lectin or an epitope-bearing portion thereof may be used as antigen in serological analysis for E. histolytica infection or as an immunogen for protection against infection. Recombinant production in procaryotic systems provides antigens or immunogens which are immunologically reactive.
Torso weighting, using the balance-based torso-weighting (BBTW) method, is an intervention that addresses balance by first challenging stability in standing using a series of perturbations (nudges) and resisted rotations to people. Challenging stability allows the assessor to determine directional instability. Once the direction of instability is determined, small weights are placed on a vest-like garment and retesting of balance occurs. In this study, participants will be tested with no weights (NW), with sham weights (SW), and with BBTW weighting (WT). Following non-weighted baseline assessment, participants will be randomly allocated into the sham weight condition or BBTW weight condition in a cross-over design. The initial condition (NW) will last four weeks and the final two conditions (SW,WT) will last two weeks each. Following each condition, outcome measures will be reassessed. Throughout the study, participants will be asked to wear a commercially-available remote monitoring device (e.g., Fitbit Flex) and keep a daily log of physical activity and number of falls. During the SW and WT conditions, participants will wear the assigned garment for 2-4 hours daily.
The invention provides a traditional Chinese medicine compound enema preparation which is prepared from the following raw material medicines in parts by mass: 10-15 parts of radix bupleuri, 10-15 parts of radix scutellariae, 12-15 parts of oriental wormwood, 13-15 parts of fructus gardeniae, 10-15 parts of mangnolia officinalis, 10-15 parts of immature bitter orange, 10-18 parts of rhizoma corydalis, 12-16 parts of radix paeoniae alba, 20-35 parts of dandelion, 22-36 parts of folium isatidis, 20-40 parts of houttuynia cordata, 12-20 parts of rheum officinale and 25-35 parts of mirabilite. The invention adopts the compatibility of the traditional Chinese medicines, and has stronger adaptability compared with the traditional Chinese medicine external application. And can be repeatedly applied for many times. Has the characteristics of diminishing inflammation, promoting gastrointestinal motility, improving intestinal permeability and balancing intestinal flora. The compound Chinese medicine preparation is absorbed in intestinal mucosa to raise the treating effect. The enema is safer and more effective than oral administration.
An anticancer cathepsin preparation which contains, as the active ingredient, cathepsin E and/or an active fragment consisting of the active site thereof or containing the active site thereof. The above-described anticancer cathepsin preparation inhibits the growth of cancer cells alone and prevents the metastasis thereof without exerting any undesirable effect on normal cells. Moreover, it can induce apoptosis in cancer cells. When used in combination with another anticancer agent, it can potentiate the sensitivity thereof even to a cancer to which the existing anticancer agents show no sensitivity. Owing to the sensitivity-potentiating effect, the therapeutic effect on cancer can be remarkably enhanced. By potentiating the sensitivity of the anticancer agent, furthermore, the dose of the anticancer agent per se can be decreased and, in its turn, the side effects, etc. of the anticancer agent can be largely reduced.
The invention relates to an anti-inflammatory painkiller for treating wound. The painkiller comprises raw Chinese chestnut and rapeseed oil. Weight ratio of raw Chinese chestnut to rapeseed oil is 1:1-20. The preparation method comprises the following steps: (1) crushing raw Chinese chestnut to obtain raw Chinese chestnut particles for later use; and (2) adding the raw Chinese chestnut particles into the rapeseed oil according to the above ratio, sealing and immersing for 6-12 months so as to obtain the anti-inflammatory painkiller for treating wound. Materials are convenient to obtain and the raw materials are easily available. The prepared medicine has a remarkable curative effect. Anti-inflammatory pain-relieving and healing rate is more than one time faster than medicines for treating wound in the market. The raw materials used in the invention are all food-grade raw materials, contains no irritating substances, are mild and have no side effect. The preparation method is simple; the preparation difficulty is low; and the preparation method is convenient to operate and implement and is worthy of promotion and use.
Over the past few years, there has been a surge in interest regarding the connection between sleep duration and quality, sleep disorders, mainly Obstructive sleep apnoea (OSA) and Vitamin D. There is growing evidence to support a new role of Vitamin D in the maintenance and regulation of optimal sleep. Furthermore, a notable link has been identified between OSA and a decrease in serum Vitamin D levels, which appears to intensify as the severity of sleep apnea worsens. Vitamin D status could also potentially serve as a mediator or provide an explanation for the association between OSA and cardiometabolic morbidity, but the current state of research in this area is inadequate. Studies have indicated that the supplementation of Vitamin D can optimize sleep quality, presenting more proof of the connection between insufficient vitamin D levels and sleep disorders. However, it is unclear whether low serum Vitamin D levels are a contributing factor to OSA development or if OSA predisposes individuals to Vitamin D deficiency. As a result, various studies have endeavored to examine the complex relationship between OSA and Vitamin D deficiency. In children and adolescents, while data is limited, there seems also to be a link between sleep disorders and Vitamin D levels. Therefore, the objective of this review is to provide a comprehensive overview of the current evidence on the association between Vitamin D and sleep disorders in both adults and children.
Intradermal/Subcutaneous injections of recMAGE-A3 + AS15 ASCI. Requires an injection site biopsy at Day 8 and Day 50.
OBJECTIVE: Patients with axial spondyloarthritis (axSpA) often experience significant delay between symptom onset and diagnosis for reasons that are incompletely understood. We investigated associations between demographic, medical, and socioeconomic factors and axSpA diagnostic delay.
METHODS: We identified patients meeting modified New York criteria for ankylosing spondylitis (AS) or 2009 Assessment of Spondyloarthritis International Society criteria for axSpA in the Mass General Brigham health care system between December 1990 and October 2021. We determined the duration of diagnostic delay, defined as the duration of back pain symptoms reported at diagnosis, as well as disease manifestations and specialty care prior to diagnosis from the electronic health record. We obtained each patient's Social Vulnerability Index (SVI) by mapping their address to the US Centers for Disease Control SVI Atlas. We examined associations among disease manifestations, SVI, and diagnostic delay using ordinal logistic regression.
RESULTS: Among 554 patients with axSpA who had a median diagnostic delay of 3.8 years (interquartile range 1.1-10), peripheral arthritis (odds ratio [OR] 0.65, 95% confidence interval [CI] 0.45-0.93) and older age at symptom onset (OR 0.83, 95% CI 0.78-0.88 per five years) were associated with shorter delay. AS at diagnosis (OR 1.85, 95% CI 1.30-2.63), a history of uveitis prior to diagnosis (OR 2.77, 95% CI 1.73-4.52), and higher social vulnerability (defined as national SVI 80th to 99th percentiles; OR 1.99, 95% CI 1.06-3.84) were associated with longer diagnostic delay.
CONCLUSION: Older age at back pain onset and peripheral arthritis were associated with shorter delay, whereas uveitis was associated with longer diagnostic delay. Patients with higher socioeconomic vulnerability had longer diagnostic delay independent of clinical factors.